Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitapivat - Agios Pharmaceuticals

Next Previous
Drug Profile

Mitapivat - Agios Pharmaceuticals

Alternative Names: AG 348; AG 348-sulfate-hydrate; Mitapivat-sulfate; PYRUKYND

Latest Information Update: 30 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antianaemics; Benzene derivatives; Cyclopropanes; Piperazines; Quinolines; Small molecules; Sulfonamides
  • Mechanism of Action Pyruvate kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Inborn error pyruvate metabolism disorders; Thalassaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Inborn error pyruvate metabolism disorders
  • Registered Thalassaemia
  • Phase III Haemolytic anaemia
  • Phase II/III Sickle cell anaemia
  • Preclinical Hereditary spherocytosis

Most Recent Events

  • 19 Nov 2025 Agios plans a pre-supplemental New Drug Application (sNDA) meeting with the US FDA for Sickle cell disease in the first quarter of 2026
  • 19 Nov 2025 Agios plans to submit a marketing application for Sickle cell disease in the US
  • 19 Nov 2025 Efficacy and adverse events data from phase II/III RISE UP clinical trials in Sickle cell anaemia released by Agios Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top